The canine endocrine testing market is projected to grow from USD 1.8 billion in 2026 to USD 3.4 billion by 2036, at a CAGR of 6.5%. Thyroid function tests will dominate with a 34.0% market share, while hypothyroidism will lead the application segment with a 38.0% share.